The BCI will attend the JFHOD to present "The Oncological Impact of Adjuvant Chemotherapy After Rectal Resection for Cancer in the TNT Era: Results of Two Randomized Controlled Trials: GRECCAR 4 and PRODIGE 23."
The results presented in this trial are from two randomized controlled trials, GRECCAR 4 and PRODIGE 23, in which the BCI participated.
This congress will discuss the placement or not of a stoma depending on the patients' risk factors (GRECCAR 17 trial) but also the organ preservation strategy and the management of patients with rectal cancer with a near-complete response (GRECCAR 20 trial).
We are delighted to be organizing JFCCR2025 for the second consecutive year!
This conference, taking place in Bordeaux, provides an opportunity to address various topics related to surgery, such as rectal cancer, colon cancer, inflammatory diseases (IBD and UC), robotic surgery in the colorectal region, complication management, and shared medical decision-making.
The Bordeaux Colorectal Institute team is organizing, in collaboration with the TivoliClinic, a colorectal cancer screening awareness day on Tuesday March 25, 2025 from 9 a.m. to 5 p.m.
This event will be an opportunity to meet around workshops organized by health professionals (dietician, surgeons, gastroenterologist) and health prevention professionals (League Against Cancer) to advise you and answer your questions.
HOW TO OBTAIN A KIT?
An active member of the IRCAD faculty, BCI will discuss the topic of management of patients with rectal cancer close to the anal canal.
This meeting is an opportunity to address complex pelvic surgery and the complication of rectovaginal fistula.
The ACM is an essential annual conference where the BCI will discuss in this 2025 edition the subject of Watch & Wait in patients with rectal cancer in sub-complete response after neoadjuvant treatment: "Near complete clinical response is suitable for W&W".
Each year the BCI is delighted to be present as a speaker at the Towards New Standards Symposium and to discuss perfect rectal surgery performed by robot and the importance of local excision which should be integrated into future protocols.
Honored to be invited to the CRSA congress with many international experts to discuss the French policy on organ preservation from the first to the last randomized trial of the GRECCAR group (from GRECCAR 2 to GRECCAR 20).
It is always a great pleasure to go to Brazil to discuss the role of neoadjuvant chemotherapy in organ preservation (GRECCAR 12 randomized trial of the GRECCAR group) and to moderate the session on the assessment of tumor response after neoadjuvant treatment.
Other topics on surgical techniques such as the use of fluorescence in routine practice were also discussed.
220 rue Mandron
33000 Bordeaux
+33 (0)5 47 50 15 75
